Our Vision

To create a world where no one has to live with an autoimmune disease

Our Mission

We are developing a novel therapeutic platform, known as Antigenic Immune Modulation (AIM), designed to cure, improve, halt or prevent autoimmune disease.

Our first application is Type 1 Diabetes (T1D), with a pipeline that includes psoriasis, rheumatoid arthritis and multiple sclerosis.

The Opportunity

Around 10% of the population will experience an autoimmune disease in their lifetime, including 8.4 million Type 1 Diabetes patients worldwide.

Autoimmune diseases profoundly affect lives as well as being a burden on healthcare and economic systems. They include Type 1 Diabetes, Multiple Sclerosis, Psoriasis, Rheumatoid Arthritis, SLE, Myasthenia Gravis and Celiac Disease.

Phaim is developing a brand new category of medicines designed to target autoimmune diseases. Our initial focus is Type 1 Diabetes due to the global prevalence and incidence rate, which continues to grow year on year.

There is currently no cure or preventative therapeutic for Type 1 Diabetes, only solutions to manage the disease.

Phaim exists to change this.

Learn More

Meet our team

“When we started Phaim, many asked, 'Why focus on autoimmunity and type 1 diabetes? Why not choose something 'easier'?' The answer is simple: we are not here for what is easy; we are here for what matters. We choose the difficult path because it holds the potential for real impact. We believe in making a difference, no matter how challenging the journey.”

- Nara Daubeney, Co-Founder & CEO of Phaim

Our News

Professor Michael Cheung is appointed as Non-Executive Director

August 2024
Michael, the Director of Cardiology at The Royal Children's Hospital in Melbourne, joins Phaim. He comes with deep expertise in clinical research trials and knowledge of the Australian landscape.

Read more
Phaim Pharma poised to trial drug that resets immune system to treat T1D

May 2022
Now is a good time to be involved with type 1 diabetes (T1D) research, according to a U.K. biotech that hopes to reduce or cut the need for insulin injections to treat the condition.

Read more
BIA publish Phaim Pharma blog on World Diabetes Day

November 2021
What does Phaim do, how does the technology work and what does the future look like?

Read more
Phaim leadership team's paper published in the International Journal of Molecular Science

February 2020
A novel method assessing the success of diabetes intervention therapy: The Type1 Diabetes Mellitus Metabolic Recovery Index.

Read more
Appointment of Dr. Annalisa Jenkins as Non-Executive Chairman

March 2019
Annalisa brings with her decades of experience in the pharmaceutical sector and we look forward to a wonderful working relationship.

Read more